Latest News

Looking At The Value Of NGS-Based Diagnostic Testing For Lung Cancer Patients

July 24, 2018 | Daryl Pritchard of PMC is featured on this podcast from the Cambridge Healthtech Institute for the Next Generation Diagnostics Summit. Pritchard discusses the chicken-or-the-egg conundrum of building evidence and gaining access, a study looking at the cost effectiveness of using NGS for clinical practice, challenges in the diagnostic reimbursement community, and more. Here is a sample of the discussion that takes place. Podcast

CHI: What challenges that face the diagnostic reimbursement community right now do you think will be fixed in the next five years? What challenges do you anticipate we will face in the future?

Daryl Pritchard: Well, as the evidence continues to be developed about the value of personalized medicine and diagnostics, I think the coverage situation will become more consistent, and these diagnostic tests will be covered when they have clear value to the system. The challenges that we'll then focus on will be about reimbursement payment levels. We continue to face a downward pricing pressure and will continue to face downward pricing pressure. We should continue to see a movement towards value-based practice and payment models.